ADARx and City Therapeutics' IPO moves Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 25 September, 2026

September 28: Don Ingber of the Wyss Institute joins our Endpoints 11 virtual day for a fireside chat, alongside interviews with the honorees and gala highlights. Open to everyone, free to join. Register now.

presented by Every­body op­ti­mizes the first 20% of pa­tient re­cruit­ment. Tri­als fall apart in the oth­er 80%.

news Novo does another small deal, this time with drug delivery biotech Nanexa The next Alnylam? RNAi biotech City Therapeutics files for IPO ADARx prices $446.3M Nasdaq debut, continuing industry's IPO momentum Peer Review Travere CEO Eric Dube on deciding to leave; Roche tees up a board seat for ex-Takeda chief

Oct 08 11:00 am ET Site-central discordance in oncology trial imaging: New benchmarks and management strategies sponsored by Perceptive Imaging Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel

Vice President, Regulatory Affairs Hinge Bio, Inc. Redwood City, CA, USA Team Leader, Analytical Research & Development (ARD) Veranova Devens, MA 01434, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

ENDPOINTS PHARMA FDA nominee Overton backs swifter trials, dodges calls to rebuke Trump if needed Elevar wins first FDA approval with second-line drug for bile duct cancer FDA approves Eli Lilly's once-weekly insulin pen, setting up rivalry with Novo

in case you missed it 1. Merck’s return to ophthalmology snags first success 2. Acadia drug fails mid-stage study in Alzheimer's psychosis, leading to modified Phase 3 3.